Tropifexor (LJN-452) is a potent, non-steroidal, selective FXR agonist with an EC50 value of 0.2 nM, with preclinical studies demonstrating its efficacy in two mouse models of NASH, where it significantly reduced steatohepatitis, decreased hepatic triglycerides, and reversed established liver fibrosis [120]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.